BioXcel stock craters after disclosure of investigator’s falsified safety report in Alzheimer’s study

BioX­cel tout­ed da­ta Thurs­day morn­ing claim­ing that Igal­mi, its drug for ag­i­ta­tion episodes, suc­ceed­ed in a piv­otal tri­al with Alzheimer’s pa­tients, re­duc­ing a com­pos­ite of symp­toms such as poor im­pulse con­trol and hos­til­i­ty.

But the biotech made on­ly a brief and opaque men­tion in its press re­lease that a prin­ci­pal in­ves­ti­ga­tor on the study was cit­ed by the FDA for a num­ber of bad prac­tices, in­clud­ing fab­ri­cat­ing an email around re­port­ing a par­tic­i­pant’s se­ri­ous med­ical event. The New Haven, CT-based com­pa­ny buried the full de­tails at the bot­tom of an SEC fil­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN